Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

UroGen Pharma (URGN) EBT Margin: 2017-2025

Historic EBT Margin for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to -125.18%.

  • UroGen Pharma's EBT Margin fell 3161.00% to -125.18% in Q3 2025 from the same period last year, while for Sep 2025 it was -167.47%, marking a year-over-year decrease of 4288.00%. This contributed to the annual value of -137.22% for FY2024, which is 1834.00% down from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's EBT Margin is -125.18%, which was up 38.04% from -202.04% recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's EBT Margin ranged from a high of -93.56% in Q3 2024 and a low of -346.49% during Q1 2021.
  • Moreover, its 3-year median value for EBT Margin was -141.92% (2024), whereas its average is -144.57%.
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 56,644bps in 2021, then plummeted by 4,933bps in 2025.
  • Over the past 5 years, UroGen Pharma's EBT Margin (Quarterly) stood at -168.88% in 2021, then spiked by 1,312bps to -155.76% in 2022, then soared by 6,157bps to -94.19% in 2023, then tumbled by 4,774bps to -141.92% in 2024, then plummeted by 3,161bps to -125.18% in 2025.
  • Its EBT Margin stands at -125.18% for Q3 2025, versus -202.04% for Q2 2025 and -214.53% for Q1 2025.